Changchun High & New Tech (000661) announced on the evening of December 8 that, according to the National Drug Reimbursement List for Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance (2025) (Medical Insurance Notice [2025] No. 33, hereinafter referred to as the "National Reimbursement Drug List") jointly issued by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security, two drugs from the company's controlling subsidiary, Changchun GeneScience Pharmaceuticals Co., Ltd. (hereinafter referred to as "GeneScience Pharma"), have been newly included in the National Reimbursement Drug List. These are Jinsaizeng (currently the generic name is "Jinpei Growth Hormone Injection"), which was independently developed by GeneScience Pharma, and Meishiya (generic name: "Megestrol Acetate Oral Suspension"), which was introduced through cooperation.

It is reported that Jinsaizeng is the world's first long-acting growth hormone approved for market by GeneScience Pharma in January 2014. Its currently approved indications include: growth retardation in children due to endogenous growth hormone deficiency (PGHD), growth disorders in girls caused by gonadal dysgenesis (Turner syndrome), and growth retardation due to idiopathic short stature (ISS). It is the only long-acting growth hormone product in China with indications beyond PGHD and also the only long-acting growth hormone product in China with real-world data verification for long-term efficacy and safety from over 150,000 cases. Currently, Phase III clinical trials for Jinsaizeng in treating adult growth hormone deficiency and Phase II clinical trials for treating short stature in children born small for gestational age are ongoing, which will further meet the treatment needs of more patients in the future.

Meishiya was developed by Baosheng Pharmaceutical Co., Ltd., and in 2024, GeneScience Pharma obtained exclusive distribution rights and product marketing authorization holder rights for this product in Mainland China, Hong Kong, Macau, and Singapore. Its currently approved indications include: treatment of anorexia in patients with acquired immunodeficiency syndrome (AIDS) and significant weight loss in AIDS and cancer patients due to cachexia. Meishiya is innovatively improved using nanotechnology, addressing the clinical issue where cachexia patients (who are already anorexic) need to consume high-fat, high-calorie meals when taking non-nano formulations. It offers superior efficacy and faster onset, filling a treatment gap for cachexia patients, and has received direct recommendations in the *Chinese Society of Clinical Oncology Guidelines for the Diagnosis and Treatment of Tumor Anorexia-Cachexia Syndrome (2025)* and the Chinese Expert Consensus on the Diagnosis and Treatment of Cancer-Related Anorexia. At the same time, Phase I clinical trials are underway for related indications of Meishiya in preventing chemotherapy-induced nausea and vomiting.

Changchun High & New Tech stated that the inclusion of Jinsaizeng and Meishiya in the 2025 National Reimbursement Drug List reflects the National Healthcare Security Administration's recognition of the clinical value, patient benefits, and degree of innovation of these drugs. This is expected to further facilitate market promotion and increase sales volume for the relevant drugs, though the specific impact on the company's financial performance cannot yet be estimated. The new version of the National Reimbursement Drug List will officially take effect on January 1, 2026. Details regarding reimbursement policies and related information will be subject to announcements from the National Healthcare Security Administration and other relevant government departments.

The core business of Changchun High & New Tech is the research and development, production, and sales of biopharmaceuticals and traditional Chinese medicines, supplemented by real estate development and other activities. Through years of industrial planning and R&D investment, the company's business segments cover various pharmaceutical fields, including genetic engineering, biological vaccines, antibody drugs, high-end chemical drugs, and modern Chinese medicine.

According to Changchun High & New Tech's third-quarter report, the company's R&D expenses for the first three quarters increased by 22.96% year-on-year to RMB 1.733 billion, further raising its share of revenue to 17.68%. This figure not only demonstrates the company's emphasis on R&D but also indicates that Changchun High & New Tech is accelerating its transformation into an innovation-driven global pharmaceutical company.

In an announcement dated November 28, Changchun High & New Tech disclosed that its subsidiary GeneScience Pharma received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, approving the clinical trial application for GenSci142 Capsules. GenSci142 Capsules are a Class 1 innovative biological product developed by GeneScience Pharma, intended for the treatment of bacterial vaginosis. If the subsidiary's clinical trial application progresses smoothly, it will help the company broaden its business structure, optimize its product portfolio, enhance its strategic product pipeline, and improve its core competitiveness.

reference：https://finance.eastmoney.com/a/202512083585514883.html